查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球代谢药物市场 - 2023-2030年
市场调查报告书
商品编码
1290363

全球代谢药物市场 - 2023-2030年

Global Metabolism Drugs Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球代谢药物市场的价值预计在2022年为160.9436亿美元，到2030年为263.6952亿美元，整个预测期的复合增长率为6.5%。

苯丙酮尿症是一种身体无法分解氨基酸苯丙氨酸的疾病，是遗传性代谢紊乱的一种说明。几个更著名的代谢疾病包括1型糖尿病、高雪氏病、枫糖浆尿症、胱氨酸病、法布里病、哈特努普病、亨特综合征、赫勒综合征、冯-吉尔克病和遗传性血色素病。

通过治疗疾病的根本原因和采用药物来保持最佳的代谢功能，代谢紊乱的治疗需要恢复代谢平衡。

市场动态

代谢性疾病的发病率不断增加

苯丙酮尿症、瓜氨酸血症和枫糖尿症等代谢性疾病的发病率不断增加，以及治疗费用高昂，都促进了这些疾病的治疗市场的增长。推动这一增长的其他因素包括发展中国家可支配收入的增加和医疗基础设施的进步。

氨基酸补充剂的费用不断上升

为了支持动物的发育、繁殖和其他功能，以及满足动物对蛋白质的需求，预计动物饲料生产商对氨基酸的需求将增加。任何氨基酸的缺乏都可能导致动物发育缓慢，成熟较晚，对免疫或代谢刺激的反应较慢，体重低，并出现各种健康问题。

因此，氨基酸在动物饲料的制备中变得更加关键。动物饲料领域对氨基酸的需求也受到肉类消费和需求上升以及牲畜产量上升的推动。

与新陈代谢药物相关的副作用

与治疗代谢紊乱的药物相关的负面作用的特点有：心率和血压升高，胃肠道问题，失眠和睡眠障碍，口干等。

例如，总部位于日本的安斯泰来制药公司在2022年6月宣布，美国FDA对FORTIS进行了临床搁置，目前正在进行1/2期试验，同时对AT845试验进行评估，该试验是针对晚发性庞贝病成年人的研究性AAV基因替代疗法。

COVID-19影响分析

治疗代谢性疾病的药物的供应和需求受到了COVID-19大流行的影响。由于COVID-19疫苗现在是研究机构和制药公司的主要关注点，质谱仪、色谱仪和其他与代谢有关的研究工具的销售量有些下降。因此，预计2020年影响新陈代谢的药物市场将出现大幅下降。

俄罗斯-乌克兰冲突分析

俄罗斯对乌克兰的入侵影响到全世界数百万人。药品开发商势必面临整个开发过程的延误，业务连续性的丧失，以及已经上市的药品不符合规定的危险。

俄乌冲突影响了研发方面的投资，由于这个原因，原材料的进出口停止了，同时投资者在这一时期也表现出较少的兴趣，这对新陈代谢药物市场产生了影响。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按药物类别分析
  • 按适应症分类
  • 按分销渠道分类
  • 按地区分类

第四章：动态变化

  • 影响因素
    • 驱动因素
      • 氨基酸代谢的普及率提高
    • 限制因素
      • 与新陈代谢药物相关的副作用
    • 机会
      • 氨基酸补充剂的费用上升和健康益处
    • 影响分析

第五章：行业分析

  • 波特五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • COVID-19之后的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第七章：按药物类别划分

  • 抗糖尿病药物
  • 降血脂药物
  • 抗肥胖症药物
  • 甲状腺激素药物
  • 其他药物

第8章：按适应症分类

  • 糖尿病
  • 高脂血症
  • 肥胖症
  • 甲状腺功能减退症

第九章：按分销渠道分类

  • 医院药房
  • 零售药店
  • 网上药店

第十章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第11章 ：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 合併和收购分析

第十二章 ：公司简介

  • Merck Sharp and Dohme Corp
  • Novartis AG
  • Amicus Therapeutics
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • GlaxoSmithKline Plc
  • Horizon Therapeutics
  • BioMarin Pharmaceuticals

第十三章 ：附录

简介目录
Product Code: PH2967

Market Overview

The Global Metabolism Drugs Market is expected to be valued at USD 16,094.36 million in 2022 and USD 26,369.52 million by 2030, with a CAGR of 6.5% throughout the forecast period.

Phenylketonuria, a disease in which the body is unable to break down the amino acid phenylalanine, is an illustration of a genetic metabolic disorder. Several more well-known metabolic diseases include type 1 diabetes, Gaucher's disease, maple syrup urine disease, cystinosis, Fabry disease, Hartnup disease, Hunter syndrome, Hurler syndrome, Von Gierke disease, and hereditary hemochromatosis.

By treating the underlying cause of the illness and employing medications to preserve optimal metabolic function, the treatment for metabolic disorders entails restoring metabolic balance.

Market Dynamics

Increasing Prevalence Of Metabolic Disorders

The increasing prevalence of metabolic disorders like phenylketonuria, citrullinemia, and maple syrup urine disease, as well as the high cost of treatments, have all contributed to the growth of the market for treatments for these disorders. Other factors driving this growth include rising disposable income in developing nations and the advancement of healthcare infrastructure.

The Rising Expense of Amino Acid Supplements

The demand for amino acids is predicted to increase among producers of animal feed in order to support animal development, reproduction, and other functions as well as to meet the animals' need for protein. Any amino acid deficit may cause animals to develop slowly, mature later, respond less quickly to immunological or metabolic stimuli, have low body weights, and have various health issues.

As a result, amino acids are becoming more crucial in the preparation of animal feed. The need for amino acids in the animal feed sector is also being driven by rising meat consumption and demand, as well as rising livestock output.

Side Effects Associated With Metabolism Drugs

Among the characteristics that have negative effects associated with drugs for metabolic disorders are increased heart rate and blood pressure, gastrointestinal issues, insomnia and sleep disturbance, dry mouth, etc.

For instance, Astellas Pharma, a pharmaceutical company based in Japan, in June 2022, announced that the USFDA put a clinical hold on FORTIS, which is currently undergoing a Phase 1/2 trial while evaluating the AT845 trial, which was an investigational AAV gene replacement therapy for adults with Late Onset Pompe Disease.

COVID-19 Impact Analysis

The supply and demand for medications that treat metabolic disorders have been affected by the COVID-19 pandemic. Since the COVID-19 vaccine is now the primary focus of research institutions and pharmaceutical corporations, sales of mass spectrometry, chromatography, and other metabolism-related research tools have somewhat decreased. The market for medications that affect metabolism is thus anticipated to see a significant drop in 2020.

Russia- Ukraine Conflcit Analysis

Russia's invasion of Ukraine affects millions of people worldwide. Drug developers are bound to face delays throughout the development process, a loss of business continuity, and the danger of non-compliance for pharmaceuticals already on the market.

The Russia-Ukraine conflict affected the investments in R&D due to which the import and exports of raw materials stopped and also investors were showing less interest during that period, which was affecting the metabolism drugs market.

Segment Analysis

The Diabetes Segment Will Dominate The Market In The Forecast Period.

The diabetes segment is estimated to hold about 35.6% of the global metabolism drugs market as plasma-free fatty acids (FFA) are more prevalent in diabetic individuals, diabetes may affect the way some medicines attach to plasma proteins, perhaps through glycosylation or protein displacement. However, albumin and 1-acid glycoprotein plasma concentrations wouldn't alter. Contrary to experimental research, the majority of medicines' metabolic clearance in people seems to be unaltered or slightly reduced in diabetes.

Geographical Analysis

North America is the Dominating Region During The Forecast Period.

Geographically, there are four regions that make up the worldwide market for metabolic disorders: North America, Europe, Asia Pacific, and the rest of the world (RoW). Due to the availability of cutting-edge technology and the greater penetration of diabetes care services throughout the region, North America is anticipated to lead the market throughout the projected period. North America is estimated to hold about 37.8% of the global metabolism drugs market.

Due to the high incidence of diabetes among the elderly population, the United States constituted a significant regional contributor. Over 25% of Americans with diabetes are 65 years of age or older, according to the American Diabetes Association. Over the projected period, Asia Pacific is anticipated to overtake North America as the region with the largest market for metabolic disorders. The region's healthcare reforms and an increase in the number of diabetics, particularly in India, are expected to drive the growth of the Asia Pacific market.

Competitive Landscape

The major global players include: Merck Sharp and Dohme Corp, Novartis AG, Amicus Therapeutics, AstraZeneca, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Sanofi, GlaxoSmithKline Plc, Horizon Therapeutics, and BioMarin Pharmaceuticals.

  • Why Purchase the Report?
  • To visualize the global metabolism drugs market segmentation based on the drug class, indication, distribution channels and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global metabolism drugs market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global metabolism drugs market report would provide approximately 92 tables, 108 figures and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Class
  • 3.2. Snippet by Indication
  • 3.3. Snippet by Distribution Channels
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increased prevalence of amino acid metabolism
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects associated with metabolism drugs
    • 4.1.3. Opportunity
      • 4.1.3.1. The rising expense of amino acid supplements and Health Benefits
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Antidiabetic Drugs
  • 7.2. Lipid Lowering Drugs
  • 7.3. Anti- Obesity Drugs
  • 7.4. Thyroid Hormone Drugs
  • 7.5. Others

8. By Indications

  • 8.1. Diabetes
  • 8.2. Hyperlipidemia
  • 8.3. Obesity
  • 8.4. Hypothyroidism

9. By Distribution Channel

  • 9.1. Hospital Pharmacies
  • 9.2. Retail Pharmacies
  • 9.3. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Merck Sharp and Dohme Corp
  • 12.2. Novartis AG
  • 12.3. Amicus Therapeutics
  • 12.4. AstraZeneca
  • 12.5. Boehringer Ingelheim International GmbH
  • 12.6. Takeda Pharmaceutical Company Limited
  • 12.7. Sanofi
  • 12.8. GlaxoSmithKline Plc
  • 12.9. Horizon Therapeutics
  • 12.10. BioMarin Pharmaceuticals

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us